Source:http://linkedlifedata.com/resource/pubmed/id/19245434
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2009-5-11
|
pubmed:abstractText |
Unmethylated cytosine-phosphorothioate-guanine containing oligodeoxynucleotides (CpG-ODN) is known as a ligand of toll-like receptor 9 (TLR9), which selectively activates type-1 immunity. We have already reported that the vaccination of tumor-bearing mice with liposome-CpG coencapsulated with model-tumor antigen, ovalbumin (OVA) (CpG + OVA-liposome) caused complete cure of the mice bearing OVA-expressing EG-7 lymphoma cells. However, the same therapy was not effective to eradicate Lewis lung carcinoma (LLC)-OVA-carcinoma. To overcome the refractoriness of LLC-OVA, we tried the combination therapy of radiation with CpG-based tumor vaccination. When LLC-OVA-carcinoma intradermally (i.d.) injected into C57BL/6 became palpable (7-8 mm), the mice were irradiated twice with a dose of 14 Gy at intervals of 24 h. After the second radiation, CpG + OVA-liposome was i.d. administered near the draining lymph node (DLN) of the tumor mass. The tumor growth of mice treated with radiation plus CpG + OVA-liposome was greatly inhibited and approximately 60% of mice treated were completely cured. Moreover, the combined therapy with radiation and CpG + OVA-liposome allowed the augmented induction of OVA-tetramer(+) LLC-OVA-specific cytotoxic T lymphocyte (CTL) in DLN of tumor-bearing mice. These results indicate that the combined therapy of radiation with CpG-based tumor vaccine is a useful strategy to eradicate intractable carcinoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
1349-7006
|
pubmed:author |
pubmed-author:AshinoShigeruS,
pubmed-author:ChamotoKenjiK,
pubmed-author:KitamuraHidemitsuH,
pubmed-author:NishimuraTakashiT,
pubmed-author:OhkuriTakayukiT,
pubmed-author:OmatsuTokuhikoT,
pubmed-author:ShiratoHirokiH,
pubmed-author:TakeshimaTsuguhideT,
pubmed-author:TogashiYujiY,
pubmed-author:WakitaDaikoD
|
pubmed:issnType |
Electronic
|
pubmed:volume |
100
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
934-9
|
pubmed:meshHeading |
pubmed-meshheading:19245434-Animals,
pubmed-meshheading:19245434-Cancer Vaccines,
pubmed-meshheading:19245434-Carcinoma, Lewis Lung,
pubmed-meshheading:19245434-Combined Modality Therapy,
pubmed-meshheading:19245434-Immunotherapy,
pubmed-meshheading:19245434-Lung Neoplasms,
pubmed-meshheading:19245434-Mice,
pubmed-meshheading:19245434-Mice, Inbred C57BL,
pubmed-meshheading:19245434-Oligodeoxyribonucleotides
|
pubmed:year |
2009
|
pubmed:articleTitle |
Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells.
|
pubmed:affiliation |
Division of Immunoregulation, Hokkaido University, Sapporo 001-0021, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|